Singapore Immunology Network, A(∗)STAR, 8A Biomedical Grove, Singapore 138648, Singapore.
Singapore Immunology Network, A(∗)STAR, 8A Biomedical Grove, Singapore 138648, Singapore; Emerging Infectious Disease Program, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; Inserm U1015, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France.
Immunity. 2021 Aug 10;54(8):1825-1840.e7. doi: 10.1016/j.immuni.2021.06.013. Epub 2021 Jul 15.
Hepatocellular carcinoma (HCC) often develops following chronic hepatitis B virus (HBV) infection and responds poorly to immune checkpoint blockade. Here, we examined the antigen specificities of HCC-infiltrating T cells and their relevance to tumor control. Using highly multiplexed peptide-MHC tetramer staining of unexpanded cells from blood, liver, and tumor tissues from 46 HCC patients, we detected 91 different antigen-specific CD8 T cell populations targeting HBV, neoantigen, tumor-associated, and disease-unrelated antigens. Parallel high-dimensional analysis delineated five distinct antigen-specific tissue-resident memory T (Trm) cell populations. Intratumoral and intrahepatic HBV-specific T cells were enriched for two Trm cell subsets that were PD-1TOX, despite being clonally expanded. High frequencies of intratumoral terminally exhausted T cells were uncommon. Patients with tumor-infiltrating HBV-specific CD8 Trm cells exhibited longer-term relapse-free survival. Thus, non-terminally exhausted HBV-specific CD8 Trm cells show hallmarks of active involvement and effective antitumor response, implying that these cells could be harnessed for therapeutic purposes.
肝细胞癌 (HCC) 常发生于慢性乙型肝炎病毒 (HBV) 感染之后,对免疫检查点阻断的反应较差。在这里,我们研究了 HCC 浸润性 T 细胞的抗原特异性及其与肿瘤控制的相关性。我们使用高度多重肽-MHC 四聚体染色技术,对来自 46 名 HCC 患者的血液、肝脏和肿瘤组织中的未扩增细胞进行检测,发现了 91 种针对 HBV、新抗原、肿瘤相关和与疾病无关抗原的不同抗原特异性 CD8 T 细胞群体。平行的高维分析描绘了五个不同的抗原特异性组织驻留记忆 T (Trm) 细胞群体。肿瘤内和肝内 HBV 特异性 T 细胞富含两种 Trm 细胞亚群,尽管它们是克隆扩增的,但 PD-1TOX 阳性。肿瘤内终末耗竭 T 细胞的高频率并不常见。具有肿瘤浸润性 HBV 特异性 CD8 Trm 细胞的患者表现出更长的无复发生存期。因此,非终末耗竭的 HBV 特异性 CD8 Trm 细胞表现出积极参与和有效抗肿瘤反应的特征,这意味着这些细胞可以被用于治疗目的。